全文获取类型
收费全文 | 12741篇 |
免费 | 1371篇 |
国内免费 | 421篇 |
专业分类
耳鼻咽喉 | 193篇 |
儿科学 | 290篇 |
妇产科学 | 340篇 |
基础医学 | 1597篇 |
口腔科学 | 604篇 |
临床医学 | 1311篇 |
内科学 | 2180篇 |
皮肤病学 | 160篇 |
神经病学 | 832篇 |
特种医学 | 377篇 |
外国民族医学 | 3篇 |
外科学 | 1709篇 |
综合类 | 1079篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 807篇 |
眼科学 | 341篇 |
药学 | 1250篇 |
7篇 | |
中国医学 | 355篇 |
肿瘤学 | 1096篇 |
出版年
2024年 | 22篇 |
2023年 | 155篇 |
2022年 | 337篇 |
2021年 | 508篇 |
2020年 | 363篇 |
2019年 | 479篇 |
2018年 | 500篇 |
2017年 | 420篇 |
2016年 | 399篇 |
2015年 | 605篇 |
2014年 | 736篇 |
2013年 | 751篇 |
2012年 | 928篇 |
2011年 | 967篇 |
2010年 | 727篇 |
2009年 | 554篇 |
2008年 | 735篇 |
2007年 | 707篇 |
2006年 | 673篇 |
2005年 | 594篇 |
2004年 | 517篇 |
2003年 | 426篇 |
2002年 | 365篇 |
2001年 | 238篇 |
2000年 | 218篇 |
1999年 | 202篇 |
1998年 | 140篇 |
1997年 | 138篇 |
1996年 | 124篇 |
1995年 | 77篇 |
1994年 | 89篇 |
1993年 | 90篇 |
1992年 | 91篇 |
1991年 | 98篇 |
1990年 | 95篇 |
1989年 | 89篇 |
1988年 | 76篇 |
1987年 | 59篇 |
1986年 | 41篇 |
1985年 | 30篇 |
1984年 | 27篇 |
1983年 | 19篇 |
1982年 | 15篇 |
1981年 | 15篇 |
1980年 | 15篇 |
1979年 | 12篇 |
1978年 | 8篇 |
1977年 | 15篇 |
1975年 | 9篇 |
1974年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
We previously reported the discovery of 14 channels in the human body, which possessed the biophysical property of high emission of light. In this study we found the same property on the Ren and Du channels in healthy rats. Additionally, we discovered that the luminance of the related channels in rat models with different "syndromes" varied greatly. For instance, a markedly low luminance appeared on the Du channel in animals with experimental syndrome of Yang deficiency induced by hydrocortisone; while in animals with experimental syndrome of blood deficiency caused by bleeding, an apparently low luminance occurred on the Ren channel. The intensity of the emitted light on Du and Ren channels increased after acupuncture treatment, but not significantly. This phenomenon conforms to the theory in traditional Chinese medicine that the Du channel is the "sea of Yang channels", while the Ren channel is the "sea of Yin channels". 相似文献
72.
H Wang A Sarrieau D Pélaprat B P Roques A Vanhove N Kopp Z Q Chi W Rostène 《Synapse (New York, N.Y.)》1991,8(3):177-184
Binding properties and localization of [3H]ohmefentanyl, a new ligand for mu opioid receptors, were investigated on normal human brain sections. Binding assays performed at the level of the basal ganglia revealed: (1) a steady-state binding reached after 60 min incubation at room temperature, (2) the presence, in saturation experiments, of an apparent single class of binding sites with a Kd = 1.68 +/- 0.45 nM and a Bmax = 162 +/- 9 fmol/mg protein, (3) an order of potency to inhibit [3H]ohmefentanyl binding as follows: ohmefentanyl greater than [D-Ala2, MePhe4, Gly-ol5] enkephalin (DAGO) greater than ethylketocyclazocine (EKC) much greater than Tyr-D-Ser(OtBu)-Gly-Phe-Leu-Thr(OtBu) (BUBU) and U-50,488H. Quantitative autoradiography showed an heterogeneous distribution of [3H]ohmefentanyl binding sites with the highest densities in amygdala, medical geniculate body, thalamus, and caudate nucleus. Binding characteristics and anatomical distribution also show that [3H]ohmefentanyl may bind to a small proportion of additional sites called "DAGO-inaccessible [3H]ohmefentanyl specific binding sites." [3H]Ohmefentanyl binding to these sites can be partly inhibited by sigma ligands such as 1,3-di-o-tolylguanidine (DTG) and haloperidol. However, unlabeled DAGO inhibited more than 80% of [3H]ohmefentanyl specific binding in most of the human brain regions studied, suggesting that the major population of sites labeled by [3H]ohmefentanyl represented mu opioid receptors. 相似文献
73.
康莱特联合化学药物动脉灌注治疗转移性肝癌的临床研究 总被引:2,自引:0,他引:2
目的:观察康莱特联合化学药物动脉灌注治疗转移性肝癌的疗效。方法:152例转移性肝癌患者随机分为治疗组(康莱特联合化学药物动脉灌注)79例、对照组(化学药物动脉灌注)73例。结果:治疗组的稳定率为87.3%,1年生存率为73.4%,2年生存率为50.6%,均明显高于对照组;并可减低血液高凝状态,提高患者的细胞免疫功能,缓解化疗药物的毒副反应,改善患者的生活质量。结论:康莱特联合化学药物动脉灌注治疗转移性肝癌有较好的疗效。 相似文献
74.
药物不良事件的防范研究 总被引:6,自引:2,他引:6
目的:探讨心内科病房药物不良事件(ADE)的防范特征。方法:由药师深入心内科病房,集中监测药物不良事件。主要监测内容是药物不良事件的存在与否,可否防范及严重程度。结果:5个月研究期间共鉴定ADE64次,其中28%可以防范。在重度ADE中,50.0%可防范;在中度ADE中,33.3%可防范;在轻度ADE中,可防范的比例最少,为13.6%。结论:药物不良事件中有相当一部分可以防范,而且越是严重的ADE就越有可能被防范。应该采取有效的措施来防范药物不良事件。 相似文献
75.
葡萄胎p53、p21~(CIP1)及p185蛋白表达与恶变的关系 总被引:2,自引:0,他引:2
目的 :探讨葡萄胎p5 3、p2 1CIP1及p185蛋白表达与恶变的关系及其临床特点。方法 :免疫组化法检测葡萄胎标本中p5 3、p2 1CIP1及p185蛋白的表达 ,以侵蚀性葡萄胎及绒癌为对照 ,并回顾性分析其临床资料。结果 :葡萄胎组p5 3、p2 1CIP1、p185蛋白阳性表达率分别为 35 % (35 / 10 0 ) ,71% (71/ 10 0 )及 36 % (36 / 10 0 ) ,与恶性对照组相比均有显著性差异 (P <0 .0 5 ) ;而完全性与部分性葡萄胎 ,完全性葡萄胎恶变组与非恶变组之间差异均无显著性 (P >0 .0 5 ) ,但恶变组p2 1CIP1表达有降低趋势。结论 :p5 3、p2 1CIP1及p185蛋白表达改变与葡萄胎恶变无确定关系 ,但可作为晚期现象出现于恶性滋养细胞肿瘤中 ,其中p2 1CIP1蛋白表达降低提示滋养细胞有向恶性转化的倾向 相似文献
76.
Wolfram syndrome (WS) is a rare autosomal recessive neurodegenerative disorder. The responsible gene, WFS1, was identified in 1998 and over 66 mutations have been reported since then. We report 2 siblings in a Taiwanese family with WS. They had similar clinical courses, including successive development of diabetes mellitus, optic atrophy, diabetes insipidus, hearing impairment, and urological complications from age 5 to 15 years. Rapid progression of systemic and neurological symptoms was noted in the elder brother. Mutation analysis of the 2 probands revealed compound heterozygotes of 1 novel and 1 previously reported mutation. Their parents and an asymptomatic sibling were carriers of 1 mutation. 相似文献
77.
S Bydder NA Spry DRH Christie D Roos BH Burmeister H Krawitz S Davis DJ Joseph M Poulsen M Berry 《Journal of Medical Imaging and Radiation Oncology》2003,47(3):284-288
The purpose of this study was to prospectively examine the effectiveness and tolerability of a simple radiotherapy technique for the palliation of symptomatic liver metastases. Twenty‐eight patients with symptomatic liver metastases were enrolled from seven centres, and received targeted (partial or whole) liver irradiation consisting of 10 Gy in two fractions over 2 days. Symptoms at baseline were hepatic pain (27 patients), abdominal distension (19), night sweats (12), nausea (18) and vomiting (eight). Twenty‐two patients (76%) had failed previous treatment with chemotherapy, hormonal therapy and/or high‐dose steroids. Symptoms and potential toxicities were prospectively assessed at the time of treatment, then 2, 6 and 10 weeks later. Individual symptom response rates were 53?66% at 2 weeks. Partial or complete global symptomatic responses were noted in 15 patients (54%) overall. The treatment was well tolerated with two patients (7%) experiencing grade 3 toxicity (one vomiting and one diarrhoea); however, four patients reported temporary worsening of pain shortly after treatment. This simple and well‐tolerated treatment achieves useful palliation. 相似文献
78.
D S Ernst I F Tannock E W Winquist P M Venner L Reyno M J Moore K Chi K Ding C Elliott W Parulekar 《Journal of clinical oncology》2003,21(17):3335-3342
PURPOSE: To compare the incidence of palliative response in patients with hormone-resistant prostate cancer (HRPC) treated with mitoxantrone and prednisone (MP) plus clodronate with that of patients treated with MP plus placebo. MATERIALS AND METHODS: Men with HRPC, bone metastases, and bone pain were randomly assigned to receive clodronate 1,500 mg administered intravenously (IV) or placebo every 3 weeks, in combination with mitoxantrone 12 mg/m2 IV every 3 weeks and prednisone 5 mg orally bid. Patients completed the present pain intensity (PPI) index and Prostate Cancer-Specific Quality-of-Life Instrument at each treatment visit and used a diary to record analgesic use on a daily basis. The primary end point was a reduction to zero or of two points in the PPI or a decrease of 50% in analgesic intake, without increase in either. RESULTS: The study accrued 209 eligible patients over 44 months. One hundred sixty patients (77%) had mild PPI scores (1 or 2), and 49 (24%) had moderate PPI scores (3 or 4). The primary end point of palliative response was achieved in 46 (46%) of 104 patients on the clodronate arm and in 41 (39%) of 105 patients on the placebo arm (P =.54). The median duration of response, symptomatic disease progression-free survival, overall survival, and overall quality of life were similar between the arms. Subgroup analysis suggested possible benefit in patients with more severe pain. CONCLUSION: MP provides useful palliation in symptomatic men with HRPC. Clodronate does not increase the rate of palliative response or overall quality of life. Clodronate may be beneficial to patients who have moderate pain, but this requires further confirmation. 相似文献
79.
加味通关液超声雾化吸入治疗Ⅱ型呼吸衰竭的临床观察 总被引:2,自引:0,他引:2
为观察中药超声雾化对呼吸衰竭的疗效,采用本院研制的加味通关液超声雾化吸入治疗Ⅱ型呼吸衰竭患者27例,并与可拉明组30例对照。结果显示:治疗组临床治愈显效率70.3%,SaO_2上升达38.4%,咳嗽、呼吸困难、咯痰好转率、平均治疗时间与对照组比较均有显著性差异(P<0.05)。 相似文献
80.
中药治疗前后单纯疱疹性角膜炎外周血T细胞亚群检测 总被引:3,自引:0,他引:3
观察中药治疗前后单纯疱疹性角膜炎外周血T细胞亚群变化。方法:将112例单纯疱疹性角膜炎患者随机分为中药观察组60例和西药对照组52例。对其中68例进行了外周血T细胞亚群检测。结果:1.观察组治愈52例;对照组治愈37例;两组差异有显著性。2.治疗后外周血T细胞亚群OKT4增加,OKT8下降,OKT4/T8比值上升。结论;中药可以改变单纯疱疹性角膜炎患者的免疫失调状态,对增强免疫力有积极作用。 相似文献